Merck & Co., Inc. Net Income Declines by 11% to $1,793 Million in Q2
Published: Jul 30, 2012
Merck & Co has stated lower net profit of $1,793 million during the second quarter ended June 2012 as compared to$2,024 million in the corresponding period of last year. Its net sales improved only by one per cent to $12,311 million from $12,151 million. Its pharmaceutical sales grew by 2 per cent to $10.6 billion largely reflect strong sales growth for Januvia, Victrelis, Janumet, Singulair, Isentress and Gardasil. These increase partially offset by expected declines in sales of Cozaar and Hyzaar as well as European austerity measures. Sales from emerging markets accounted for approximately 18 per cent of pharmaceutical sales in the second quarter. China continues to be a key driver with 27 per cent growth for the second quarter, including a four percent benefit from foreign exchange.